Journal
INTERNATIONAL JOURNAL OF CARDIOLOGY
Volume 201, Issue -, Pages 247-252Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.ijcard.2015.08.103
Keywords
Ezetimibe; Statins; Cholesterol; Cardiovascular events; Mortality
Categories
Ask authors/readers for more resources
Background: The addition of ezetimibe to statin therapy has been widely demonstrated to significantly reduce low-density lipoprotein cholesterol levels. However, the efficacy of ezetimibe in reducing CV events and its safety has been less investigated. The aim of the current meta-analysis was to report efficacy and safety of ezetimibe from randomized clinical trials. Methods: Randomized clinical trials with a follow-up of at least 24 weeks, enrolling more than 200 patients, comparing ezetimibe versus placebo or ezetimibe plus another hypolipidemic agent versus the same hypolipidemic drug alone and reporting at least one event among all-cause and CV mortality, myocardial infarction (MI), stroke and new onset of cancer were included in the analysis. Results: 7 trials enrolling 31,048 patients (median follow-up 34.1 +/- 26.3 months; 70% women; mean age 61 +/- 8 years) were included in the analysis. Compared to control therapy, ezetimibe significantly reduced the risk of MI by 13.5% (RR: 0.865, 95% CI: 0.801 to 0.934, p < 0.001) and the risk of any stroke by 16.0% (RR: 0.840, 95% CI: 0.744 to 0.949, p = 0.005), without any effect on all-cause and CV mortality (RR: 1.003, 95% CI: 0.954 to 1.055, p = 0.908; RR: 0.958, 95% CI: 0.879 to 1.044, p = 0.330; respectively) and risk of new cancer (RR: 1.040, 95% CI: 0.965 to 1.120, p = 0.303). Conclusions: Ezetimibe significantly reduces the risk of MI and stroke without any effect on all-cause and CV mortality and risk of cancer. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available